Colin Bristow
Stock Analyst at UBS
(1.74)
# 3,369
Out of 5,149 analysts
105
Total ratings
40.32%
Success rate
-1%
Average return
Main Sectors:
Stocks Rated by Colin Bristow
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ENGN enGene Holdings | Maintains: Neutral | $4 → $10 | $9.66 | +3.52% | 3 | Nov 12, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Buy | $553 → $546 | $474.27 | +15.12% | 16 | Nov 7, 2025 | |
| GILD Gilead Sciences | Maintains: Neutral | $108 → $112 | $147.83 | -24.24% | 4 | Aug 8, 2025 | |
| PTCT PTC Therapeutics | Maintains: Buy | $71 → $80 | $64.39 | +24.24% | 4 | Jul 29, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Buy | $12 → $5 | $4.80 | +4.17% | 3 | Jun 17, 2025 | |
| ALXO ALX Oncology Holdings | Maintains: Buy | $1.2 → $1 | $2.07 | -51.69% | 6 | May 21, 2025 | |
| IMVT Immunovant | Downgrades: Neutral | $38 → $17 | $26.71 | -36.35% | 6 | Apr 22, 2025 | |
| AMGN Amgen | Maintains: Neutral | $315 → $319 | $377.00 | -15.38% | 9 | Apr 14, 2025 | |
| ABOS Acumen Pharmaceuticals | Maintains: Buy | $6 → $4 | $3.31 | +20.85% | 4 | Mar 28, 2025 | |
| PFE Pfizer | Maintains: Neutral | $29 → $28 | $26.58 | +5.34% | 13 | Feb 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $125 → $120 | $119.83 | +0.14% | 7 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $234 → $202 | $184.02 | +9.77% | 10 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $56 → $16 | $1.60 | +900.00% | 5 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,090 → $1,099 | $766.66 | +43.35% | 1 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $164 → $167 | $15.87 | +952.30% | 5 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $428 → $420 | $1,007.73 | -58.32% | 1 | Dec 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $12 → $2 | $11.64 | -82.82% | 2 | Dec 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $2.21 | +714.48% | 1 | Oct 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $154 → $146 | $233.86 | -37.57% | 2 | Aug 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $73 → $75 | $61.22 | +22.51% | 1 | Jul 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $64 → $26 | $2.95 | +781.36% | 1 | Apr 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $4.91 | +83.30% | 1 | Aug 23, 2021 |
enGene Holdings
Nov 12, 2025
Maintains: Neutral
Price Target: $4 → $10
Current: $9.66
Upside: +3.52%
Vertex Pharmaceuticals
Nov 7, 2025
Maintains: Buy
Price Target: $553 → $546
Current: $474.27
Upside: +15.12%
Gilead Sciences
Aug 8, 2025
Maintains: Neutral
Price Target: $108 → $112
Current: $147.83
Upside: -24.24%
PTC Therapeutics
Jul 29, 2025
Maintains: Buy
Price Target: $71 → $80
Current: $64.39
Upside: +24.24%
Rocket Pharmaceuticals
Jun 17, 2025
Maintains: Buy
Price Target: $12 → $5
Current: $4.80
Upside: +4.17%
ALX Oncology Holdings
May 21, 2025
Maintains: Buy
Price Target: $1.2 → $1
Current: $2.07
Upside: -51.69%
Immunovant
Apr 22, 2025
Downgrades: Neutral
Price Target: $38 → $17
Current: $26.71
Upside: -36.35%
Amgen
Apr 14, 2025
Maintains: Neutral
Price Target: $315 → $319
Current: $377.00
Upside: -15.38%
Acumen Pharmaceuticals
Mar 28, 2025
Maintains: Buy
Price Target: $6 → $4
Current: $3.31
Upside: +20.85%
Pfizer
Feb 5, 2025
Maintains: Neutral
Price Target: $29 → $28
Current: $26.58
Upside: +5.34%
Jan 8, 2025
Maintains: Buy
Price Target: $125 → $120
Current: $119.83
Upside: +0.14%
Oct 3, 2024
Maintains: Neutral
Price Target: $234 → $202
Current: $184.02
Upside: +9.77%
Aug 9, 2024
Maintains: Neutral
Price Target: $56 → $16
Current: $1.60
Upside: +900.00%
Apr 17, 2024
Maintains: Buy
Price Target: $1,090 → $1,099
Current: $766.66
Upside: +43.35%
Mar 1, 2024
Maintains: Buy
Price Target: $164 → $167
Current: $15.87
Upside: +952.30%
Dec 15, 2022
Maintains: Buy
Price Target: $428 → $420
Current: $1,007.73
Upside: -58.32%
Dec 8, 2022
Downgrades: Neutral
Price Target: $12 → $2
Current: $11.64
Upside: -82.82%
Oct 18, 2022
Initiates: Buy
Price Target: $18
Current: $2.21
Upside: +714.48%
Aug 1, 2022
Maintains: Neutral
Price Target: $154 → $146
Current: $233.86
Upside: -37.57%
Jul 28, 2022
Maintains: Neutral
Price Target: $73 → $75
Current: $61.22
Upside: +22.51%
Apr 18, 2022
Maintains: Buy
Price Target: $64 → $26
Current: $2.95
Upside: +781.36%
Aug 23, 2021
Initiates: Buy
Price Target: $9
Current: $4.91
Upside: +83.30%